Investor Presentation: First Nine Months of 2020
65
Investor presentation
First nine months of 2020
Phase 3 programme on-going investigating concizumab for
haemophilia A and B irrespective of inhibitor status
Phase 3 trials with data expected first half of 2021
Novo NordiskⓇ
Arm 1: No prophylaxis
Arm 2: Concizumab
prophylaxis
Arm 3: Concizumab
prophylaxis
Exp7 and Exp8:
On-demand treatment
Exp7 and Exp8:
Phase 2 patients on
concizumab prophylaxis
Exp7 (with inhibitors):
Prophylaxis with bypassing or
on-demand
Arm 4: Concizumab
prophylaxis
Extension with
concizumab
prophylaxis
.
.
Characteristics and next steps
High affinity, humanised monoclonal IgG4
antibody
First-in-class anti-TFPI boosting the initiation
phase to restore haemostasis
• Delivered once-daily in a convenient
Flextouch® pen
• Safe and well-tolerated in phase 2 and efficacy
comparable to factor replacement
Exp8 (without inhibitors):
Prophylaxis with factor
replacement or on-demand
Main part:
24 weeks treatment
<
Extension:
Up to 136 weeks treatmentView entire presentation